# Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted Volunteers

> **NCT05558462** · NA · COMPLETED · sponsor: **Valenta Pharm JSC** · enrollment: 24 (actual)

## Conditions studied

- Influenza
- Respiratory Viral Infection

## Interventions

- **DRUG:** XC8

## Key facts

- **NCT ID:** NCT05558462
- **Lead sponsor:** Valenta Pharm JSC
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-22
- **Primary completion:** 2022-11-11
- **Final completion:** 2022-12-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05558462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05558462, "Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted Volunteers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05558462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*